Duloxetine Hydrochloride (HCI) + Placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Sclerosis

Conditions

Multiple Sclerosis

Trial Timeline

Oct 1, 2008 โ†’ Nov 1, 2010

About Duloxetine Hydrochloride (HCI) + Placebo

Duloxetine Hydrochloride (HCI) + Placebo is a phase 3 stage product being developed by Eli Lilly for Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00755807. Target conditions include Multiple Sclerosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00755807Phase 3Completed

Competing Products

20 competing products in Multiple Sclerosis

See all competitors